Outcomes of Dolutegravir Use in Children and Adolescents Living With HIV-1 in Sub-Saharan Africa

July 18-21, 2021; Virtual
Large, retrospective analysis illustrates viral suppression with and tolerability of dolutegravir-based regimens in children and adolescents who were treatment naive or suppressed on previous regimens.
Format: Microsoft PowerPoint (.ppt)
File Size: 242 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Milena Murray and Clinical Care Options (CCO): Current pharmacokinetic and safety data support the use of tenofovir alafenamide during pregnancy

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 15, 2021

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Dr Jason Halperin and Clinical Care Options (CCO): Rapid ART in adolescents leads to virologic suppression and upholds equity

Jason Halperin, MD, MPH Released: September 10, 2021

Dr Jason Halperin and Clinical Care Options (CCO): Medication treatment for OUD improves HIV viral suppression rates

Jason Halperin, MD, MPH Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue